Drug profile · INN
plazomicin sulfate
ZEMDRI
plazomicin sulfate (ZEMDRI) is a bacterial 70s ribosome inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — plazomicin sulfate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
plazomicin sulfate (ZEMDRI) is a bacterial 70s ribosome inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is plazomicin sulfate?
plazomicin sulfate (ZEMDRI) is a bacterial 70s ribosome inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for plazomicin sulfate?
ZEMDRI is a marketed brand name for plazomicin sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of plazomicin sulfate?
plazomicin sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.